Correlation between Serum Erythropoietin and Cerebral Collateral Flow in Acute Ischemic Stroke Patient

Article information

Korean J Fam Med. 2023;44(1):53-57

Publication date (electronic) : 2023 January 19

doi : https://doi.org/10.4082/kjfm.22.0117

Sung Won Yun¹, Won Yong Kim¹, Jun Beom Lee^,2

¹Department of Family Medicine, Hong-Ik Hospital, Seoul, Korea

²Department of Neurology, Hong-Ik Hospital, Seoul, Korea

Corresponding Author: Jun Beom Lee https://orcid.org/0000-0002-7361-3161 Tel: +82-2-2600-0578, Fax: +82-2-2697-4605, E-mail: acupunct@hanmail.net

Received 2022 June 14; Revised 2022 August 18; Accepted 2022 October 8.

Abstract

INTRODUCTION

The clinical outcome of patients with acute ischemic stroke is poor if the serum erythropoietin (EPO) level is high [1]. However, transient cerebral ischemia or small infarction occurred in patients with previously known severe stenosis, leading to better outcomes. This phenomenon, called “ischemic preconditioning,” involves EPO [2]. Although the previous results may seem contradictory, EPO level increases in the condition of acute stroke to alleviate symptom worsening. In patients with previously known intra- and extracranial stenosis, preventatively elevated EPO suppresses brain cell death and can alleviate symptom worsening. The collateral cerebral circulation affects stroke prognosis. Despite stenosis or narrowing of the main cerebral blood vessels, the prognosis is favorable if the collateral blood circulation is well developed [3]. In this context, EPO and cerebral collateral circulation could be correlated. To date, no study has examined whether the degree of collateral circulation development is correlated with EPO in the acute stage of stroke. The present study investigated for the first time whether there is a correlation between cerebral collateral circulation degree and EPO level.

METHODS

2. Cerebral Collateral Circulation Assessment

In patients with no contraindications for the radio-contrast injection (specifically, contrast allergy or serum creatinine levels >1.5 mg/dL), high-resolution CT angiography (CTA) was performed on a 512-section multidetector helical scanner (Aquilion One; Toshiba Medical Systems, Otawara, Japan), and images were acquired with a 70-mL bolus injection of contrast at 3 mL/s followed by 30 mL of saline at 3 mL/s into the antecubital vein. Scanning was triggered using bolus tracking, with the region of interest placed in the posterior aortic arch and the trigger threshold set at 150 Hounsfield units. The scan parameters at Hongik Hospital were as follows: section thickness, 1 mm; no section gap; field of view, 200 mm; matrix, 512×512; 100–120 mAs; and 100 kVp. Coverage extended from the base of the skull to the vertex, and the source images were reformatted into 3-mm-thick axial, coronal, and sagittal projections. Maximum-intensity projections were routinely provided as part of CTA, and no three-dimensional reconstructions were performed. Each CTA study was evaluated for intracranial collaterals according to the Mass system (Figure 1) [4], a 5-point score that compares collaterals on the affected versus unaffected sides. The Mass system uses Sylvian fissure vessels or leptomeningeal collaterals as internal controls. The score ranges were: 5 (exuberant), 4 (more than those on the contralateral side), 3 (equal to those on the contralateral side), 2 (less than those on the contralateral side), and 1 (no vessel opacification). Scores of 3–5 were considered good collaterals (GC), while those of 1–2 were considered poor collaterals (PC). A brain CT perfusion study was conducted after patient consent was obtained.

Figure. 1.

Mass system. (A) No vessel opacification (arrow). (B) Less opacification than on the contralateral side (arrow). Opacification equal to that on the contralateral side is not shown. (C) More opacification than on the contralateral side (arrow). (D) Exuberant opacification is shown (arrow).

RESULTS

A total of 56 subjects were enrolled (GC, 22; PC, 34). The basic characteristics of the participants are summarized in Table 1. The frequencies of chronic heart failure (CHF), hospitalization days (HOD), and mRS were higher in the PC group (P<0.05), whereas the frequencies of chronic kidney disease (CKD) and initial EPO were higher in the GC group (P<0.05). Other characteristics such as hemoglobin level, body mass index, prevalence of hypertension, diabetes, dyslipidemia, initial NIHSS score, and Alberta stroke program Early CT Score did not differ significantly between the two groups (P>0.05).

Table 1.

Basic characteristics in subjects

The initial serum EPO level was 85.4% higher (11.5±3.8 mIU/mL versus 6.3±2.1 mIU/mL) in the GC versus PC group. Additionally, the correlation coefficient analysis showed a positive correlation between an elevated serum EPO level and GC after the adjustment for other variables, such as CHF, CKD, HOD, initial NIHSS score, and mRS score (r=0.712, P=0.042). The ROC curve analysis showed that the serum EPO cut-off value for GC was 9.1 mIU/mL with a sensitivity and specificity of 0.79 and 0.86, respectively (area under the curve, 0.888; standard error, 0.044; 95% confidence interval, 0.801–0.974; P<0.001) (Figure 2, Table 2).

Figure. 2.

Receiver operating characteristic (ROC) curve of serum erythropoietin and a good collateral (GC). High serum erythropoietin levels showed a positive correlation with GC after that adjustment for other variables such as chronic heart failure, National Institute of Health Stroke Scale, chronic kidney disease, Alberta Stroke Program Early Computed Tomography Score, and hospitalization day (r=0.712, P=0.04).

Table 2.

EPO and mRS between different collateral groups

DISCUSSION

The present study investigated the correlation between initial serum EPO level and cerebral collateral circulation and analyzed the serum EPO cut-off level (9.1 mIU/mL) for GC. EPO is a peptide produced by the kidneys that increases erythropoiesis by suppressing erythroid precursor apoptosis in the bone marrow to counteract anemia [5]. EPO and its receptors are located in the brain and regulated in response to ischemic stroke [6]. An increase in serum EPO level is associated with better functional outcome in ischemic stroke [7]. Collateral cerebral blood flow in patients with acute ischemic stroke can be evaluated via a CT perfusion study using the collateral index, which showed better clinical outcomes [8].

EPO levels are elevated in coronary chronic total occlusion patients and they had better coronary collateral vessel grade with reduced mortality [9]. On the other hand, there was also conflicting result suggesting that initial elevated EPO level is associated with poor outcome in ischemic stroke [1]. The authors suggested that EPO is mainly a direct indicator of previous anemia, which is a known negative factor for stroke severity and recovery. There is another negative phase II/III clinical study that failed to show positive effects of intravenously administered EPO within 48 hours after stroke onset. However, it should be noted that chronic severe anemia or vessel stenosis significantly stimulates the growth of collaterals [10]. The mean subject age was relatively low. In contrast, no significant correlation was noted between anemia and collaterals in the present study. However, our findings suggest that the elevated serum EPO levels in patients with acute cerebral infarction who visited the emergency department is probably related to the previous development of the cerebral collateral circulation. This is because a previous prospective study revealed that serum EPO concentration continues to increase during the acute stroke period to recover functional outcome [11]. Therefore, our data for elevated serum EPO from the initial acute stroke period implicates previously programmed protective mechanisms from brain injury, such as collateral flow.

A normal EPO level allows sufficient erythrocytes to replace dead cells in the blood and maintain oxygen flow to the renal oxygen sensor to ensure baseline levels of EPO synthesis [12]. The red blood cell production and mass are regulated by EPO and reduced oxygen in arterial blood due to anemia results in increased EPO production [13]. EPO also acts as an angiogenic factor and regulates angiogenesis [14]. Endothelial cell migration and proliferation are the key features in the angiogenic process and are stimulated by recombinant human EPO [15]. Another benefit of a high serum EPO level involves its neuroprotective feature and promotion of the regeneration of injured neurons after stroke [16]. However, in the acute stage of ischemic stroke, GC circulation is the most important finding that may lead to successful reperfusion in ischemic stroke and improve stroke outcome with thrombolytic and endovascular therapy [17]. Therefore, an initial high serum EPO concentration in acute ischemic stroke patients could be a good predictor of GC, leading to a good prognosis. Due to this advantage, it is clinically meaningful that the present study determined an accurate serum EPO cut-off value (9.1 mIU/mL) for GC to provide standards that can be referenced in emergency stroke treatment.

Article information Continued